New Levels of Excellence in Pharmaceutical Formulations for a Better Life!
Since its inception in 1966, the Ciron Group of Companies has been involved in developing a growing portfolio of best-in-class pharmaceutical formulations in the health care arena. With a vision of providing quality and affordable generic products to the society, Mr. R.T. Shah commenced a small company, which has now grown into a large and dynamic group. Currently, Ciron marks a leading position in the field of pharmaceutical formulations manufacturing and export.
Our Corporate Headquarters is located in Mumbai, India with manufacturing units in Tarapur & Palghar (approx 2.5 hours from Mumbai International Airport).
About Ciron Drugs and Pharmaceuticals pvt. ltd.
CIRON Group has built up a reputation for excellence and superiority on the foundations of consistently high quality, constantly expanding product portfolio, timely deliveries, and state-of-the-art manufacturing facilities, conforming to the most stringent as well demanding international standards.
We have earned accolades from our customers not only in domestic market but also in the international market due to our indefatigable and determined commitment towards quality and customer satisfaction. Today, Ciron has a regular overseas presence in over 36 countries.
An extremely high-quality combination of professionals and technology allows us to keep on top of the pinnacle of success in manufacturing a wide range of tablets, capsules, syrups, injections, ointments, and powders. Our team is headed by able and experienced managers. It comprises over 50 well-qualified technical personnel and 200 workmen, all dedicated to delivering the highest possible levels of customer satisfaction.
The company has carved a niche for itself in the sphere of operations of manufacturing Ampoules, vials, Eye /Ear / Nasal drops, Lyophilized Products and Lyophilized bulk, which are rarely manufactured in India, thus making CIRON market friendly in India and abroad.
CIRON invests almost 40% of its Annual Profits in latest plant and machinery along with training of technical personnel ensuring continuous upgrade of quality of its products in-line with excellent technology.
It is our endeavour to bring solace to the suffering humanity through effective and high-quality products, offered at competitive prices.
CIRON offers products of International Standards and keep strict control over quality and productivity at every stage. Our congenial environment; well-built infrastructure; energetic & highly competent technical staff and workforce; unique human relationship; efficient & committed management support are the pillar to practice up-to-date Quality Management Systems and thus results in meeting highest quality standards, safety, and productivity. We also produce and export a number of products in the brand name, besides the generic formulations.
Our branded pharmaceutical formulations enjoy steady demand in following countries:
Asia: Philippines, Vietnam, Sri Lanka, Indonesia, Malaysia, Cambodia, Iraq and Papua New Guinea.
Africa: Uganda, Nigeria, Ghana, Malawi, Zambia, Kenya, Mozambique, Mauritius, Madagascar, Angola, Guinea, etc.
Latin & Central America: Costa Rica, Honduras, Nicaragua, Puerto Rico, Dominican Republic, Guatemala, Guyana, Peru, Bolivia, Venezuela, and others.
Europe & USA for re-export to under developed and developing Nations: Belgium, Germany, and the USA.
The CIRON Group's strong manufacturing competence, its committed team and its continuous pursuit of total quality are all focused on further expanding CIRON's large base of satisfied clients and fulfilling its objective of becoming a world leader in formulations for the pharmaceutical industry. The Ciron Group is committed to building a mutually beneficial business relationship with both national and international customers. Importers, distributors, and agents who can introduce Ciron products in their national markets are warmly invited to contact the company.
We are looking for franchising in national and international markets.
The formulation ( the drug in a ready-to-consume form such as a tablet) in the generic market is being as Abbreviated New Drug Application (ANDA). It is called ANDA because the generic manufacturer does not have to go through the elaborate clinical trials that the original patent-holder would have to go through. Since the properties of the drug are already known, the trials for generics are limited when compared to a new drug.
The US regulatory authority looks at aspects such as bio-equivalence (the rate at which the drug is absorbed into the bloodstream) when granting approval to a generic formulation. This is to make sure that the generic drug performs with the same effectiveness as the branded drug in the human body. ANDA approvals are not an easy affair. The costs and delays are a factor to reckon with, as in the case of bulk drugs, the manufacturing facilities have to be approved by the US regulatory authorities.